Page last updated: 2024-10-25

clonidine and Abstinence Syndrome, Neonatal

clonidine has been researched along with Abstinence Syndrome, Neonatal in 32 studies

Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.

Research Excerpts

ExcerptRelevanceReference
"The study goal was to determine whether clonidine treatment of neonatal abstinence syndrome (NAS) would result in a better neurobehavioral performance compared with morphine."9.20Morphine versus clonidine for neonatal abstinence syndrome. ( Bada, HS; Breheny, P; Caldwell, R; Capilouto, G; Garlitz, K; Gibson, J; Leggas, M; Li, Y; Sithisarn, T, 2015)
"To compare the efficacy of clonidine versus phenobarbital in reducing morphine sulfate treatment days for neonatal abstinence syndrome (NAS)."9.17Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. ( Chamberlain, S; Kopcza, K; Shah, B; Singh, R; Surran, B; Visintainer, P, 2013)
"The population pharmacokinetic (PK) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome, and significant covariates affecting its PK parameters were identified."9.15Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. ( Agthe, AG; Cao, YJ; Gauda, EB; Hendrix, CW; Lee, H; Xie, HG, 2011)
"To determine if oral clonidine would reduce the duration of opioid detoxification for neonatal abstinence syndrome."9.14Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. ( Agthe, AG; Chavez-Valdez, R; Gauda, EB; Hendrix, CW; Jansson, L; Kim, GR; Lewis, TR; Mathias, KB; Yaster, M, 2009)
"To provide a systematic review of the current role of clonidine in neonatal abstinence syndrome (NAS)."8.93Role of Clonidine in Neonatal Abstinence Syndrome: A Systematic Review. ( Gildon, BL; Streetz, VN; Thompson, DF, 2016)
"To undertake a literature search and critical appraisal of best available evidence to answer the clinical question: Does the addition of clonidine (I) to standard treatment with an opioid (C) improve outcomes (O) in infants with Neonatal Abstinence Syndrome? A search of both comprehensive (MedLine and Embase) and pre-filtered databases (Dynamed, UpToDate and TRIP), utilising Boolean Operators to combine search terms appropriately."8.02Does the addition of clonidine to opioid therapy improve outcomes in infants with Neonatal Abstinence Syndrome? ( D'Abaco, E, 2021)
"To compare clonidine versus phenobarbital as adjunctive therapy in infants who failed monotherapy with morphine for neonatal abstinence syndrome (NAS)."7.96Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. ( Brusseau, C; Burnette, T; Heidel, RE, 2020)
"To examine whether adding clonidine to the morphine regimen for treatment of neonatal abstinence syndrome (NAS) is associated with a shorter length of treatment compared with morphine alone."7.91Comparison of outcomes between morphine and concomitant morphine and clonidine treatments for neonatal abstinence syndrome. ( Campbell-Yeo, M; Gullickson, C; Kuhle, S, 2019)
"Extemporaneously prepared clonidine admixture is increasingly used for the management of neonatal abstinence syndrome."7.91Physicochemical stability of extemporaneously prepared clonidine solutions for use in neonatal abstinence syndrome. ( Harmanjeet, H; Lu, D; Paine, M; Patel, RP; Peterson, GM; Wanandy, T, 2019)
"This study suggests that a treatment of neonatal abstinence syndrome with clonidine in omission of opiates is possible without causing short-term adverse cardiovascular effects."7.76Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate. ( Bastanier, C; Beske, F; Esmaeili, A; Keinhorst, AK; Schlösser, R; Schuster, T, 2010)
"The study goal was to determine whether clonidine treatment of neonatal abstinence syndrome (NAS) would result in a better neurobehavioral performance compared with morphine."5.20Morphine versus clonidine for neonatal abstinence syndrome. ( Bada, HS; Breheny, P; Caldwell, R; Capilouto, G; Garlitz, K; Gibson, J; Leggas, M; Li, Y; Sithisarn, T, 2015)
"To compare the efficacy of clonidine versus phenobarbital in reducing morphine sulfate treatment days for neonatal abstinence syndrome (NAS)."5.17Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial. ( Chamberlain, S; Kopcza, K; Shah, B; Singh, R; Surran, B; Visintainer, P, 2013)
"The population pharmacokinetic (PK) profile of oral clonidine was characterized in newborns with neonatal abstinence syndrome, and significant covariates affecting its PK parameters were identified."5.15Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome. ( Agthe, AG; Cao, YJ; Gauda, EB; Hendrix, CW; Lee, H; Xie, HG, 2011)
"To determine if oral clonidine would reduce the duration of opioid detoxification for neonatal abstinence syndrome."5.14Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial. ( Agthe, AG; Chavez-Valdez, R; Gauda, EB; Hendrix, CW; Jansson, L; Kim, GR; Lewis, TR; Mathias, KB; Yaster, M, 2009)
"To provide a systematic review of the current role of clonidine in neonatal abstinence syndrome (NAS)."4.93Role of Clonidine in Neonatal Abstinence Syndrome: A Systematic Review. ( Gildon, BL; Streetz, VN; Thompson, DF, 2016)
"To undertake a literature search and critical appraisal of best available evidence to answer the clinical question: Does the addition of clonidine (I) to standard treatment with an opioid (C) improve outcomes (O) in infants with Neonatal Abstinence Syndrome? A search of both comprehensive (MedLine and Embase) and pre-filtered databases (Dynamed, UpToDate and TRIP), utilising Boolean Operators to combine search terms appropriately."4.02Does the addition of clonidine to opioid therapy improve outcomes in infants with Neonatal Abstinence Syndrome? ( D'Abaco, E, 2021)
"To compare clonidine versus phenobarbital as adjunctive therapy in infants who failed monotherapy with morphine for neonatal abstinence syndrome (NAS)."3.96Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome. ( Brusseau, C; Burnette, T; Heidel, RE, 2020)
"To examine whether adding clonidine to the morphine regimen for treatment of neonatal abstinence syndrome (NAS) is associated with a shorter length of treatment compared with morphine alone."3.91Comparison of outcomes between morphine and concomitant morphine and clonidine treatments for neonatal abstinence syndrome. ( Campbell-Yeo, M; Gullickson, C; Kuhle, S, 2019)
" We present a case report of a neonate born to a 25-year-old mother enrolled in a medication-assisted treatment program for substance use disorder who was noncompliant in prenatal care, using multiple substances throughout the pregnancy, including gabapentin and fentanyl."3.91Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog. ( Davies, TH; Hansen, Z; Loudin, S; Murray, S; Nellhaus, EM, 2019)
"A high-performance liquid chromatography-tandem mass spectrometry method was developed and validated for the simultaneous quantification of morphine, morphine's major metabolites morphine-3-glucuronide and morphine-6-glucuronide, and clonidine, to support the pharmacokinetic analysis of an ongoing double-blinded randomized clinical trial that compares the use of morphine and clonidine in infants diagnosed with neonatal abstinence syndrome."3.91Validation of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its metabolites in human plasma. ( Bada, H; Leggas, M; Ng, CM; Tang, F, 2019)
"Extemporaneously prepared clonidine admixture is increasingly used for the management of neonatal abstinence syndrome."3.91Physicochemical stability of extemporaneously prepared clonidine solutions for use in neonatal abstinence syndrome. ( Harmanjeet, H; Lu, D; Paine, M; Patel, RP; Peterson, GM; Wanandy, T, 2019)
"This study suggests that a treatment of neonatal abstinence syndrome with clonidine in omission of opiates is possible without causing short-term adverse cardiovascular effects."3.76Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate. ( Bastanier, C; Beske, F; Esmaeili, A; Keinhorst, AK; Schlösser, R; Schuster, T, 2010)
"When opioid misuse rises in the United States, pregnant women and their neonates are affected."2.61Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. ( Jones, HE; Kraft, WK, 2019)
"Clonidine was a significantly better adjunctive therapy than phenobarbital in reducing morphine treatment days."2.61Therapeutic approaches for neonatal abstinence syndrome: a systematic review of randomized clinical trials. ( Ghazanfarpour, M; Keramat-Roudi, A; Mashhadi, ME; Mégarbane, B; Moghaddam, MMM; Najafi, MN; Rezaee, R; Roozbeh, N; Tsatsakis, A, 2019)

Research

Studies (32)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (6.25)18.2507
2000's4 (12.50)29.6817
2010's19 (59.38)24.3611
2020's7 (21.88)2.80

Authors

AuthorsStudies
Clemans-Cope, L1
Holla, N1
Lee, HC1
Cong, AS1
Castro, R1
Chyi, L1
Huang, A1
Taylor, KJ1
Kenney, GM1
Brusseau, C1
Burnette, T1
Heidel, RE1
Stephanie, A1
Caldwell, CD1
Fraser, D1
Joseph, R1
Goodall, HD1
Ridky, J1
Rudd, K1
Williams, L1
D'Abaco, E1
Merhar, SL1
Ounpraseuth, S1
Devlin, LA1
Poindexter, BB1
Young, LW1
Berkey, SD1
Crowley, M1
Czynski, AJ1
Kiefer, AS1
Whalen, BL1
Das, A1
Fuller, JF1
Higgins, RD1
Thombre, V1
Lester, BM1
Smith, PB1
Newman, S1
Sánchez, PJ1
Smith, MC1
Simon, AE1
Zankl, A2
Martin, J2
Davey, JG2
Osborn, DA5
Wachman, EM2
Schiff, DM1
Silverstein, M1
Gullickson, C1
Kuhle, S1
Campbell-Yeo, M1
Nellhaus, EM1
Murray, S1
Hansen, Z1
Loudin, S1
Davies, TH1
Tang, F1
Bada, H1
Ng, CM1
Leggas, M2
Jones, HE1
Kraft, WK1
Ghazanfarpour, M1
Najafi, MN1
Roozbeh, N1
Mashhadi, ME1
Keramat-Roudi, A1
Mégarbane, B1
Tsatsakis, A1
Moghaddam, MMM1
Rezaee, R1
Lu, D1
Harmanjeet, H1
Wanandy, T1
Paine, M1
Peterson, GM1
Patel, RP1
Parikh, A1
Gopalakrishnan, M1
Azeem, A1
Booth, A1
El-Metwally, D1
Surran, B1
Visintainer, P1
Chamberlain, S1
Kopcza, K1
Shah, B1
Singh, R2
Coyle, MG1
Visintainer, PF1
Bagley, SM1
Holland, E1
Brogly, SB1
Bada, HS1
Sithisarn, T1
Gibson, J1
Garlitz, K1
Caldwell, R1
Capilouto, G1
Li, Y1
Breheny, P1
Streetz, VN1
Gildon, BL1
Thompson, DF1
McPherson, C1
Agthe, AG2
Kim, GR1
Mathias, KB1
Hendrix, CW2
Chavez-Valdez, R1
Jansson, L1
Lewis, TR1
Yaster, M1
Gauda, EB2
Leikin, JB1
Mackendrick, WP1
Maloney, GE1
Rhee, JW1
Farrell, E1
Wahl, M1
Kelly, K1
Esmaeili, A1
Keinhorst, AK1
Schuster, T1
Beske, F1
Schlösser, R1
Bastanier, C1
Xie, HG1
Cao, YJ1
Lee, H1
Jeffery, HE3
Cole, MJ3
Bio, LL1
Siu, A1
Poon, CY1
Little, PJ1
Price, RR1
Hinton, RK1
Kuhn, CM1
Theis, JG1
Selby, P1
Ikizler, Y1
Koren, G1

Clinical Trials (12)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome[NCT02851303]Phase 461 participants (Actual)Interventional2016-10-31Completed
Pharmacological Treatment of Neonatal Abstinence Syndrome: Opiate Versus Non-Opiate[NCT01734551]Phase 431 participants (Actual)Interventional2011-09-30Completed
Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy[NCT03092011]Phase 490 participants (Anticipated)Interventional2018-02-21Recruiting
Treatment of Neonatal Abstinence Syndrome: Evaluation of Efficacy of Phenobarbital in Combination With Either Methadone or Diluted Deodorized Tincture of Opium as Stabilizing and Tapering Regiments[NCT01723722]Phase 440 participants (Actual)Interventional2007-01-31Completed
Improving Outcomes in Neonatal Abstinence Syndrome[NCT01958476]Phase 3117 participants (Actual)Interventional2013-09-30Completed
A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome[NCT01452789]Phase 363 participants (Actual)Interventional2011-11-30Completed
A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS)[NCT01708707]Phase 229 participants (Actual)Interventional2012-12-31Completed
Comparison of Clonidine Versus Phenobarbital as an Adjunct Therapy for Neonatal Abstinence Syndrome[NCT01175668]68 participants (Actual)Interventional2010-07-31Terminated (stopped due to Based on the planned interim analysis results at 50% recruitment, after IRB reviewed the results, further enrollment was stopped.)
Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain[NCT03396588]Phase 3120 participants (Actual)Interventional2017-12-07Active, not recruiting
Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial[NCT00510016]Phase 280 participants (Actual)Interventional2002-07-31Completed
Phase I-II Clinical Trial to Determine the Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia[NCT01862250]Phase 1/Phase 213 participants (Actual)Interventional2013-10-03Completed
Efficacy of Clonidine in Reducing Iatrogenic-induced Opioid Dependence in Infants:[NCT01360450]Phase 2/Phase 312 participants (Actual)Interventional2011-07-31Terminated (stopped due to The study was treminated because of low accural)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Breastfeeding Initiation and Continuation at Hospital Discharge

Assessed through chart review of discharge summary documentation of method of infant feeding at time of discharge (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days

InterventionParticipants (Count of Participants)
Morphine5
Methadone5

Length of Hospital Stay

Number of days in hospital after birth (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days

Interventiondays (Mean)
Morphine17.9
Methadone16.1

Length of Treatment

(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days

Interventiondays (Mean)
Morphine14.7
Methadone12.8

Need for Additional Agent to Treat Withdrawal, Determined by Chart Review of Medication Administration Record of Administered Medications for Withdrawal Treatment (Example: Clonidine or Phenobarbital)

clonidine (NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days

InterventionParticipants (Count of Participants)
Morphine1
Methadone0

Need for Feeding Assistance, Determined by Chart Review of Discharge Summary, Specifically Evaluating for Need for Nasogastric Tube Placement or Peripheral Parenteral Nutrition.

(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days

InterventionParticipants (Count of Participants)
Morphine11
Methadone6

Need for NICU Transfer, as Determined by Chart Review of Discharge Summary.

(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days

InterventionParticipants (Count of Participants)
Morphine0
Methadone3

Total Morphine Equivalent Dose Received

(NCT02851303)
Timeframe: assessed at hospital discharge, approximately 7-30 days

Interventionmorphine equivalents mg (Mean)
Morphine9.86
Methadone33.0

Duration of Treatment

Total number days of treatment (NCT01734551)
Timeframe: 120 days

Interventiondays (Median)
Morphine39
Clonidine27

Bayley Scales of Infant and Toddler Development Third Edition

Scores obtained Bayley Scales of Infant and Toddler Development Third Edition in the developmental domains of motor, cognitive, and language. This tool for measures of motor, cognitive and language development is a series of standardized measurements and for each domain, the standardized scores have a mean of 100 and standard deviation of 15. Scores below 1 standard deviation (= or less than 84) is considered below normal. Scores above 1 standard deviation (over 115) represent higher than normal functioning in each domain The score for each domain (motor, cognitive, and language functioning) represents the full-scale score (NCT01734551)
Timeframe: 1 year of life

,
Interventionscores on a scale (Mean)
Bayley III motorCognitiveLanguage totalLanguage ReceptiveLanguage Expressive
Clonidine95.893.395.895.099.2
Morphine97.692.998.0101.1100.0

Finnegan Neonatal Abstinence Scoring System

Mean of total Finnegan Scores obtained every 3 hours on days 2, 7, and 14 following start of treatment; A score is a number representing the total score or sum from 21 items or symptoms or manifestations of opiate withdrawal in newborn infants. The total score ranges from 0 to 43. Reference: 1. Finnegan LP, Connaughton JF, Jr., Kron RE, et al. Neonatal abstinence syndrome: assessment and management. Addict Dis 1975;2(1-2):141-58. Although normal newborn may manifest mild symptoms that will give scores in the range of 0 to 7. A score of 8 consecutively obtained times 3 indicate that infant will benefit from treatment, in this study morphine or clonidine. A decrease in scores especially to less than 8 is suggestive of a good response to treatment. (NCT01734551)
Timeframe: 14 days

,
Interventionscores on a scale (Mean)
Finnegan scores day 2 of treatmentFinnegan scores day 7 of treatmentFinnegan scores day 14 of treatment
Clonidine8.55.76.7
Morphine7.56.67.1

Neurobehavioral Performance Summary Scores From the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS)

The summary scores from the Neonatal Intensive Care Unit Network Neurobehavioral Scale (NNNS) give a measure of infant neurobehavior in the following areas (score range): habituation (1-9), regulation (2.20-7.50), attention (1.29 -8.4), Handling (0 - 1), quality of movement (1.20 - 6.20), Non-optimal reflexes (0-12), Asymmetric reflexes (0-7), arousal (2.43 - 6.67), hypertonicity (0- 8), hypotonicity (0 - 5.0), excitability (0-11), lethargy (0 - 11.0). and stress/abstinence (0. - 0.57). A higher score for each item means a higher level of the construct. For example, a higher score for hypertonicity means the infant is more hypertonic and higher score on hypotonicity means the infant is more hypotonic. No cut-off score published for normal or abnormal behavioral performance. Reference: Lester BM et al. Summary Statistics of Neonatal Intensive Care Unit Network Neurobehavioral Scale Scores From the Maternal Lifestyle Study: A Quasinormative Sample, in Pediatrics 2004; 113,668. (NCT01734551)
Timeframe: 5-10 days after treatment starts

,
Interventionscores on a scale (Mean)
AttentionHandlingQuality of movementRegulationNon-optimal reflexesAsymmetric reflexesStress/abstinenceArousalHypertonicityHypotonicityExcitabilityLethargy
Clonidine4.510.424.925.264.130.000.083.950.250.192.385.13
Morphine5.060.364.775.23.730.200.073.910.400.132.63.6

Length of Treatment With Opioid Medication

Up to 12 months (NCT01723722)
Timeframe: Up to 12 months

Interventiondays (Mean)
Deodorized Tincture Opium After Phenobarbital for Withdrawal19.1
Methadone After Phenobarbital for Withdrawal17.7

Growth Outcome: Head Circumference at 18 Months

Average head circumference growth outcome at 18 month follow-up visit. (NCT01958476)
Timeframe: 18 month follow-up visit

Interventioncm (Mean)
Methadone47.8
Neonatal Morphine Solution48.2

Growth Outcome: Length at 18 Months

Average length (cm) at 18 month follow-up visit. (NCT01958476)
Timeframe: 18 month follow-up visit

Interventioncm (Mean)
Methadone82.1
Neonatal Morphine Solution81.7

Growth Outcome: Weight Change From Birth to 18 Months

Growth outcome weight (lbs) depicted as difference in averaged weights from birth to 18 month follow-up visit. Standard deviations were averaged between birth and 18 mo time points. (NCT01958476)
Timeframe: Birth to 18 month follow-up visit

Interventionlbs (Mean)
Methadone19.1
Neonatal Morphine Solution18.7

Length of Hospital Stay (LOS)

Participants were monitored for the duration of their hospitalization, an expected mean of 22 days. (NCT01958476)
Timeframe: Participants will be monitored during their entire hospitalization, expected mean 22 days.

Interventiondays (Mean)
Methadone21.8
Neonatal Morphine Solution23.2

Length of Hospital Stay (LOS) Due to Neonatal Abstinence Syndrome (NAS)

Participants were monitored for the duration of their hospitalization attributable to NAS only. (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, expected mean 22 days.

Interventiondays (Mean)
Methadone18.9
Neonatal Morphine Solution21.1

Length of Treatment (LOT)

Total number of days infant treated with replacement opioids while admitted to the hospital. (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization.

Interventiondays (Mean)
Methadone14.7
Neonatal Morphine Solution16.6

Number of Infants Needing a Dose Increase

"One Finnegan score ≥12, or two consecutive scores ≥8 affirms the requirement for pharmacological treatment or increasing treatment dosage. If the infant continued to have two consecutive Finnegan Scores ≥8 two times consecutively, or one ≥12, the dose was increased to the next level. (Level I: 0.3 mg/kg/day) (Level II: 0.5 mg/kg/day) (Level III: 0.7 mg/kg/day)~A higher Finnegan score indicates greater severity of NAS (min 0, max 50)." (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, an average of 22 days.

InterventionParticipants (Count of Participants)
Methadone22
Neonatal Morphine Solution28

Number of Infants Needing a Second NAS Medication

Number of infants treated with a second medication following protocol, phenobarbital. If the Finnegan Score remained elevated (still scored ≥8 two times consecutively, or still scored once ≥12) despite increasing to a predetermined maximal opioid dose (methadone or morphine), phenobarbital was administered (20-mg/kg loading dose followed by 4-5 mg/kg daily). (NCT01958476)
Timeframe: Participants were monitored for the duration of their hospitalization, an average of 22 days.

InterventionParticipants (Count of Participants)
Methadone10
Neonatal Morphine Solution17

Cognitive, Language, and Motor Development From 18 Month Bayley III Neurodevelopmental Assessment

The Bayley Scales of Infant and Toddler Development (BSID-III) assesses the development of infants and children (1-42 months) through a series of developmental play tasks, identifying children with developmental delay. Raw scores of completed items are summarized within three distinct scale scores (Cognitive Scale, Language Scale, Motor Scale). Scale scores are each converted to composite scores to determine the child's performance compared with scores of age-matched children of typical development (percentile rank). A higher composite score indicates more ideal developmental outcome (range 40-160). At 18 month follow-up visit, participants were assessed using the BSID-III for cognitive, language and motor scale composite score outcomes. (NCT01958476)
Timeframe: Assessment at 18 month follow-up visit

,
Interventionscores on a scale (Composite) (Mean)
Cognitive CompositeLanguage CompositeMotor Composite
Methadone100.196.0103.6
Neonatal Morphine Solution98.194.299.1

Length of Hospitalization

This endpoint will compare length of stay in the hospital (in days) using sublingual buprenorphine or morphine solution. (NCT01452789)
Timeframe: Duration of hospital stay is an expected average of 5 weeks.

Interventiondays (Median)
Sublingual Buprenorphine21
Oral Morphine33

Length of Treatment

This endpoint will compare length of treatment (in days) using sublingual buprenorphine or oral morphine solution. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.

Interventiondays (Median)
Sublingual Buprenorphine15
Oral Morphine28

Number of Participants With Adverse Events as a Measure of Safety and Tolerability

Adverse events will be collected, graded by severity, and assessed for causality referent to study drug. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.

InterventionParticipants (Count of Participants)
Sublingual Buprenorphine7
Oral Morphine8

Number of Patients Requiring Supplemental Phenobarbital Treatment.

This endpoint will compare requirement number of patients who require use of supplemental phenobarbital. (NCT01452789)
Timeframe: Patients will be followed for the duration of hospital stay, an expected average of 5 weeks.

Interventionparticipants (Number)
Sublingual Buprenorphine5
Oral Morphine7

Length of Treatment With Neonatal Morphine Sulfate

(NCT01175668)
Timeframe: subjects were followed for the duration of treatment, up to 3 months

Interventiondays (Mean)
NMS/Clonidine18.2
NMS/Phenobarbital13.6

Total Dose of NMS Used

(NCT01175668)
Timeframe: For the duration of treatment, upto 3 months

Interventionmg/kg (Mean)
NMS/Clonidine5.7
NMS/Phenobarbital4.6

Amount of Morphine Given

Intravenous morphine (mg/kg) was given. The standard dose is 0.05 mg/kg per dose (NCT01862250)
Timeframe: Up to 2 days

Interventionmg/kg (Median)
Clonidine Infants With HIE0.02

Presence of Shivering After Clonidine

Babies were assessed after administration of clonidine for the presence or absence of shivering. (NCT01862250)
Timeframe: 48hrs

InterventionParticipants (Count of Participants)
Clonidine Infants With HIE0

Steady State Clonidine Blood Levels During Hypothermia

"Trough clonidine blood levels were measured after 4-7 doses of clonidine were given intravenously with a dosing interval of every 8 hrs. Mean and standard deviation (SD) of the number of doses given prior to levels being drawn was 5.3 (mean) and 0.37 (SD).~Time after last dose before measurement was 9hrs (mean) and 2.7hrs (SD)." (NCT01862250)
Timeframe: 3 days

Interventionng/ml (Median)
Clonidine Infants With HIE0.6

Time to Passive Rewarming

Following 2 hours of therapeutic hypothermia, the temperature of the thermo-blanket is adjusted up half degree per hour allowing passive rewarming until 36.5 degrees is reached (NCT01862250)
Timeframe: Beginning at 72 hours up to 12 hours

InterventionHours (Median)
Clonidine Infants With HIE8.7

Time to Complete Detoxification

Time to complete detoxification is defined as 48 hrs off all opioids/benzodiazepines and study drug with acceptable withdrawal scores of <9 (on average we expect the infant to be enrolled in the study for 2-4 weeks). The scale used to assess withdrawal was the Modified Finnegan Neonatal Withdrawal Scale, which ranges from 0-41, 0 represents no withdrawal and 41 represent maximum withdrawal. (NCT01360450)
Timeframe: up to 4 weeks

,
Interventiondays (Mean)
total days on narcoticsduration on study drug in days
Control37.214.2
Treatment89.521

Reviews

13 reviews available for clonidine and Abstinence Syndrome, Neonatal

ArticleYear
Sedatives for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 05-18, Volume: 5

    Topics: Bias; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Narcoti

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Opioid treatment for opioid withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2021, 07-07, Volume: 7

    Topics: Buprenorphine; Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn

2021
Neonatal Abstinence Syndrome: Advances in Diagnosis and Treatment.
    JAMA, 2018, Apr-03, Volume: 319, Issue:13

    Topics: Acupuncture Therapy; Analgesics; Breast Feeding; Buprenorphine; Clonidine; Female; Humans; Infant, N

2018
Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome.
    Clinics in perinatology, 2019, Volume: 46, Issue:2

    Topics: Analgesia, Obstetrical; Analgesics; Analgesics, Opioid; Breast Feeding; Buprenorphine; Buprenorphine

2019
Therapeutic approaches for neonatal abstinence syndrome: a systematic review of randomized clinical trials.
    Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences, 2019, Volume: 27, Issue:1

    Topics: Analgesics, Opioid; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Infant, Newborn; Le

2019
Review of the assessment and management of neonatal abstinence syndrome.
    Addiction science & clinical practice, 2014, Sep-09, Volume: 9, Issue:1

    Topics: Breast Feeding; Buprenorphine; Clonidine; Female; Humans; Infant, Newborn; Methadone; Narcotics; Neo

2014
Role of Clonidine in Neonatal Abstinence Syndrome: A Systematic Review.
    The Annals of pharmacotherapy, 2016, Volume: 50, Issue:4

    Topics: Analgesics, Opioid; Clonidine; Humans; Infant, Newborn; Neonatal Abstinence Syndrome

2016
Pharmacotherapy for Neonatal Abstinence Syndrome: Choosing the Right Opioid or No Opioid at All.
    Neonatal network : NN, 2016, Volume: 35, Issue:5

    Topics: Analgesics; Buprenorphine; Clonidine; Drug Therapy, Combination; Humans; Hypnotics and Sedatives; In

2016
Sedatives for opiate withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2010, Oct-06, Issue:10

    Topics: Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Narcotics; Ne

2010
Update on the pharmacologic management of neonatal abstinence syndrome.
    Journal of perinatology : official journal of the California Perinatal Association, 2011, Volume: 31, Issue:11

    Topics: Benzodiazepines; Buprenorphine; Clonidine; Female; Humans; Hypnotics and Sedatives; Infant, Newborn;

2011
Sedatives for opiate withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2002, Issue:3

    Topics: Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Neonatal Abst

2002
Sedatives for opiate withdrawal in newborn infants.
    The Cochrane database of systematic reviews, 2005, Jul-20, Issue:3

    Topics: Chlorpromazine; Clonidine; Diazepam; Humans; Hypnotics and Sedatives; Infant, Newborn; Neonatal Abst

2005
Current management of the neonatal abstinence syndrome: a critical analysis of the evidence.
    Biology of the neonate, 1997, Volume: 71, Issue:6

    Topics: Analgesics, Opioid; Anticonvulsants; Antipsychotic Agents; Chlorpromazine; Clinical Trials as Topic;

1997

Trials

4 trials available for clonidine and Abstinence Syndrome, Neonatal

ArticleYear
Efficacy of clonidine versus phenobarbital in reducing neonatal morphine sulfate therapy days for neonatal abstinence syndrome. A prospective randomized clinical trial.
    Journal of perinatology : official journal of the California Perinatal Association, 2013, Volume: 33, Issue:12

    Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Analysis of Variance; Clonidine; Drug Ther

2013
Morphine versus clonidine for neonatal abstinence syndrome.
    Pediatrics, 2015, Volume: 135, Issue:2

    Topics: Analgesics; Arousal; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2015
Morphine versus clonidine for neonatal abstinence syndrome.
    Pediatrics, 2015, Volume: 135, Issue:2

    Topics: Analgesics; Arousal; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2015
Morphine versus clonidine for neonatal abstinence syndrome.
    Pediatrics, 2015, Volume: 135, Issue:2

    Topics: Analgesics; Arousal; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2015
Morphine versus clonidine for neonatal abstinence syndrome.
    Pediatrics, 2015, Volume: 135, Issue:2

    Topics: Analgesics; Arousal; Clonidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ

2015
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
    Pediatrics, 2009, Volume: 123, Issue:5

    Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination;

2009
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
    Pediatrics, 2009, Volume: 123, Issue:5

    Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination;

2009
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
    Pediatrics, 2009, Volume: 123, Issue:5

    Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination;

2009
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
    Pediatrics, 2009, Volume: 123, Issue:5

    Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination;

2009
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
    Pediatrics, 2009, Volume: 123, Issue:5

    Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination;

2009
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
    Pediatrics, 2009, Volume: 123, Issue:5

    Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination;

2009
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
    Pediatrics, 2009, Volume: 123, Issue:5

    Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination;

2009
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
    Pediatrics, 2009, Volume: 123, Issue:5

    Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination;

2009
Clonidine as an adjunct therapy to opioids for neonatal abstinence syndrome: a randomized, controlled trial.
    Pediatrics, 2009, Volume: 123, Issue:5

    Topics: Adrenergic alpha-Agonists; Analgesics, Opioid; Blood Pressure; Clonidine; Drug Therapy, Combination;

2009
Clonidine clearance matures rapidly during the early postnatal period: a population pharmacokinetic analysis in newborns with neonatal abstinence syndrome.
    Journal of clinical pharmacology, 2011, Volume: 51, Issue:4

    Topics: Administration, Oral; Adrenergic alpha-2 Receptor Agonists; Clonidine; Double-Blind Method; Humans;

2011

Other Studies

15 other studies available for clonidine and Abstinence Syndrome, Neonatal

ArticleYear
Neonatal abstinence syndrome management in California birth hospitals: results of a statewide survey.
    Journal of perinatology : official journal of the California Perinatal Association, 2020, Volume: 40, Issue:3

    Topics: Analgesics, Opioid; Breast Feeding; California; Clonidine; Health Care Surveys; Humans; Infant Care;

2020
Clonidine versus phenobarbital as adjunctive therapy for neonatal abstinence syndrome.
    Journal of perinatology : official journal of the California Perinatal Association, 2020, Volume: 40, Issue:7

    Topics: Analgesics, Opioid; Clonidine; Humans; Infant, Newborn; Length of Stay; Methadone; Morphine; Neonata

2020
Academy News.
    Neonatal network : NN, 2020, 08-01, Volume: 39, Issue:5

    Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Catheter-Related Infections; Clinical Competence; Cloni

2020
Does the addition of clonidine to opioid therapy improve outcomes in infants with Neonatal Abstinence Syndrome?
    Journal of paediatrics and child health, 2021, Volume: 57, Issue:1

    Topics: Analgesics, Opioid; Clonidine; Drug Therapy, Combination; Humans; Infant; Infant, Newborn; Neonatal

2021
Phenobarbital and Clonidine as Secondary Medications for Neonatal Opioid Withdrawal Syndrome.
    Pediatrics, 2021, Volume: 147, Issue:3

    Topics: Analgesics; Analgesics, Opioid; Clonidine; Drug Administration Schedule; Drug Therapy, Combination;

2021
Comparison of outcomes between morphine and concomitant morphine and clonidine treatments for neonatal abstinence syndrome.
    Acta paediatrica (Oslo, Norway : 1992), 2019, Volume: 108, Issue:2

    Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Clonidine; Drug Therapy, Combination; Fema

2019
Novel Withdrawal Symptoms of a Neonate Prenatally Exposed to a Fentanyl Analog.
    Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners, 2019, Volume: 33, Issue:1

    Topics: Anticonvulsants; Clonidine; Female; Fentanyl; Humans; Infant, Newborn; Levetiracetam; Methadone; Myo

2019
Validation of a HPLC/MS method for simultaneous quantification of clonidine, morphine and its metabolites in human plasma.
    Biomedical chromatography : BMC, 2019, Volume: 33, Issue:7

    Topics: Chromatography, High Pressure Liquid; Clonidine; Drug Stability; Humans; Infant, Newborn; Limit of D

2019
Physicochemical stability of extemporaneously prepared clonidine solutions for use in neonatal abstinence syndrome.
    Journal of clinical pharmacy and therapeutics, 2019, Volume: 44, Issue:6

    Topics: Clonidine; Drug Packaging; Drug Stability; Drug Storage; Glass; Humans; Infant, Newborn; Neonatal Ab

2019
Racial association and pharmacotherapy in neonatal opioid withdrawal syndrome.
    Journal of perinatology : official journal of the California Perinatal Association, 2019, Volume: 39, Issue:10

    Topics: Analgesics; Black or African American; Clonidine; Drug Therapy, Combination; Female; Humans; Infant,

2019
Adjunctive therapy for neonatal opioid dependence: do we really know what's best?
    Journal of perinatology : official journal of the California Perinatal Association, 2014, Volume: 34, Issue:7

    Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Clonidine; Female; Humans; Male; Morphine;

2014
Adjunctive therapy for neonatal abstinence syndrome: why not personalize it for each infant based on their in-utero exposure?
    Journal of perinatology : official journal of the California Perinatal Association, 2014, Volume: 34, Issue:7

    Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics, Opioid; Clonidine; Female; Humans; Male; Morphine;

2014
Use of clonidine in the prevention and management of neonatal abstinence syndrome.
    Clinical toxicology (Philadelphia, Pa.), 2009, Volume: 47, Issue:6

    Topics: Administration, Oral; Adrenergic alpha-Agonists; Clonidine; Drug Therapy, Combination; Female; Gesta

2009
Treatment of neonatal abstinence syndrome with clonidine and chloral hydrate.
    Acta paediatrica (Oslo, Norway : 1992), 2010, Volume: 99, Issue:2

    Topics: Blood Pressure; Chloral Hydrate; Clonidine; Drug Therapy, Combination; Female; Humans; Hypnotics and

2010
Role of noradrenergic hyperactivity in neonatal opiate abstinence.
    Drug and alcohol dependence, 1996, Volume: 41, Issue:1

    Topics: Adrenergic alpha-Agonists; Animals; Animals, Newborn; Brain; Clonidine; Humans; Infant, Newborn; Met

1996